Now you can get access to the latest and highest-quality analysis of recent Wall Street buying and selling ideas with just one subscription to Beyond the Wall Investing ! There is a free trial and a special discount of 10% for you. Join us today!Before you dive into my today's article on Rockwell Medical, Inc. (NASDAQ: RMTI ), I want to say right off the bat that my previous "Buy" rating on RMTI wasDaniel Sereda is chief investment analyst at a family office whose investments span continents and diverse ass ...

Rockwell Medical, Inc. (NASDAQ:RMTI) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Heather Hunter - Senior Vice President & Chief Corporate Affairs Officer Mark Strobeck - President & Chief Executive Officer Jesse Neri - Senior Vice President of Finance Conference Call Participants Anthony Venditti - Maxim Group Operator Good morning and welcome to Rockwell Medical's Third Quarter 2024 Results Conference Call and Webcast. Please note, this event is being recorded. At thi ...

Rockwell Medical (RMTI) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to loss of $0.07 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 400%. A quarter ago, it was expected that this maker of products used in the treatment of kidney disease and anemia would post a loss of $0.04 per share when it actually produced earnings of $0.01, delivering a surpri ...

United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q __________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-23661 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in i ...

Rockwell Medical Reports Third Quarter 2024 Earnings, Generates Profitability on a Cash Flow and Adjusted EBITDA Basis for the Second Consecutive Quarter • Reports net product sales of $28.3 million for the third quarter of 2024, an increase of 31% over net product sales for the same period in 2023. Net product sales for the third quarter of 2024 included a special large order of premium-priced products by our largest customer. • Reports gross profit of $6.2 million for the third quarter of 2024, an increas ...

Rockwell Medical (RMTI) is scheduled to report third-quarter 2024 results on Nov. 11, before the opening bell.In the last reported quarter, the company’s adjusted earnings of 1 cent exceeded the Zacks Consensus Estimate by 125%. Rockwell Medical beat estimates in each of the trailing four quarters, the average positive surprise being 87.92%.The Zacks Consensus Estimate for third-quarter revenues is pegged at $25.9 million, suggesting growth of 9.3% year over year. The consensus estimate for third-quarter ea ...

Good times continue for Rockwell Medical (RMTI) stock. Back-to-back big announcements over the recent months, like the company's new launches for home hemodialysis, a multi-million-dollar distribution agreement in Japan and a product purchase agreement with the leading at-home and acute care dialysis provider in the United States, have generated significant optimism among the investors. Added to this, the latest recognition as the "2024 Fortune Best Workplaces in Manufacturing and Production List" in the sm ...

Rockwell Medical (RMTI) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices. The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate. Individual investors oft ...

Rockwell Medical (RMTI) delivered an impressive performance through 2024, with its stock witnessing more than 108% year-to-date surge, outperforming the 15.5% rise of the industry and the benchmark's 18.1% increase. The company also strongly outperformed its key rivals like EDAP TMS (EDAP) and IRIDEX (IRIX) year to date. EDAP TMS has fallen 40.3% and IRIDEX has declined 32.3% during this period. Image Source: Zacks Investment Research YTD Share Comparison This year can be regarded as a momentous period for ...

Dobri Dobrev/E+ via Getty Images Investment Thesis After a few complicated years with revenue that didn't grow as much, a gross margin that was even negative and numerous changes in CEOs, Mr. Mark Strobeck arrived at Rockwell Medical (NASDAQ:RMTI) in 2022 to completely turn around the situation and currently it has even reached the first quarter net income profitable, something unthinkable a few years ago. If the expectation is met and the gross margin expands to 25% from now to 2028 (the expectation is tha ...